Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Prostate Cancer|Metastatic Castration-resistant Prostate Cancer|Castration Resistant Prostatic Cancer
BIOLOGICAL: JANX007|DRUG: Darolutamide
Incidence of Dose Limiting Toxicities (DLT), 3 years|Incidence of Adverse Events (AE) and Serious Adverse Events (SAE), 3 years
Area under the concentration time curve to infinity of JANX007 (AUC0-inf), Pre-dose and at multiple timepoints post-dose on Days 1, 2, 4, 8, 9, 15, 16, 18 up to end of treatment (Up to 3 years)|Maximum observed concentration of JANX007 (Cmax), Pre-dose and at multiple timepoints post-dose on Days 1, 2, 4, 8, 9, 15, 16, 18 up to end of treatment (Up to 3 years)|Number of participants who develop anti-drug antibodies against JANX007, Up to 3 years|Duration of Response, Time from documentation of complete response or partial response to disease progression using RECIST v1.1 and PCWG3, Up to 3 years|Prostate Specific Antigen (PSA) response, Best reduction in PSA level achieved confirmed by a second PSA test â‰¥21 days later, Up to 3 years|Radiographic Progression Free Survival (rPFS), Time from treatment initiation to radiographic evidence of disease progression using RECIST v1.1 and PCWG3, Up to 3 years|Overall Response Rate, Proportion of participants who achieve a complete response or partial response using RECIST v1.1 and PCWG3, Up to 3 years|Overall Survival, Time from treatment initiation until death from any cause, Up to 3 years
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).